Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.61 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.61 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.61 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | AVPR2 | P30518 | 6/20 | 0.54 |
| ▸ | SMO | Q99835 | 2/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1458777 | 0.90 | CHRNB2 (0.63) | CHRNB2CHRNB4CHRNA3CHRNA4TP53 | |
| Hydrochloric Acid SCHEMBL2960791 | 0.89 | CHRNB2 (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4TP53 | |
| SCHEMBL7342820 | 0.87 | KDM4E (0.61) | TP53ALDH1A1LMNAGAAKDM4E | |
| SCHEMBL5234812 | 0.86 | GAA (0.61) | CHRNB2CHRNB4CHRNA3CHRNA4TP53 | |
| SCHEMBL7372274 | 0.84 | TP53 (0.55) | CHRNB2CHRNB4CHRNA3CHRNA4TP53 | |
| SCHEMBL7334315 | 0.81 | DHODH (0.68) | TP53ALDH1A1LMNAAVPR1APOLB | |
| SCHEMBL2571007 | 0.80 | CHRNB2 (0.73) | CHRNB2CHRNB4CHRNA3CHRNA4TP53 | |
| SCHEMBL10820021 | 0.80 | TP53 (0.51) | CHRNB2CHRNB4CHRNA3CHRNA4TP53 | |
| SCHEMBL7611559 | 0.80 | CHRNB2 (0.68) | CHRNB2CHRNB4CHRNA3CHRNA4TP53 | |
| SCHEMBL8609977 | 0.79 | KDM4E (0.59) | TP53ALDH1A1LMNAGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763605-B2 | [1,4]benzodiazepines as vasopressin V2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-7763605-B2 | [1,4]benzodiazepines as vasopressin V2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-27 | — | — | US | disclosed |
| US-7763605-B2 | [1,4]benzodiazepines as vasopressin V2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-07-27 | — | — | US | disclosed |
| EP-1809296-A4 | NOVEL [1,4]BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2009-03-11 | — | — | EP | disclosed |
| EP-1809296-A2 | NOVEL [1,4]BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-25 | — | — | EP | disclosed |
| US-20060116367-A1 | Novel [1,4]benzodiazepines as vasopressin V2 receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006049984-A2 | NOVEL [1,4]BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
| WO-2006049984-A2 | NOVEL [1,4]BENZODIAZEPINES AS VASOPRESSIN V2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-11 | — | — | WO | disclosed |
| EP-0804438-B1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | WYETH CORP (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-0915876-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1997049707-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5700796-A | USEFUL FOR TREATING CONGESTIVE HEART FAILURE, DISEASE CONDITIONS WITH EXCESS RENAL WATER REABSORPTION AND CONDITIONS WITH INCREASED VASULAR RESISTANCE AND CORONARY VASOCONSTRICTION | AMERICAN CYANAMID COMPANY (US) | 1997-12-23 | — | — | US | disclosed |
| EP-0804438-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0804420-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | American Cyanamid Company (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0804419-A1 | QUINOLINE DERIVATIVES AS TACHYKININ NK 3 RECEPTOR ANTAGONISTS | SmithKline Beecham Farmaceutici S.p.A. (IT) | 1997-11-05 | — | — | EP | disclosed |
| US-5612334-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5610156-A | USED IN TREATING DISEASES CHARACTERIZED BY EXCESS RENAL REABSORPTION OF WATER | AMERICAN CYANAMID COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1996022293-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022282-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5536718-A | Tricyclic benzazepine vasopressin antagonists | AMERICAN CYANAMID COMPANY (US) | 1996-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116367-A1 | Novel [1,4]benzodiazepines as vasopressin V2 receptor antagonists | AVPR2, AVPR1B, AVPR1A | CHRNB2 455/4885CHRNB4 449/4885CHRNA3 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.